[1]
|
中国医师协会心血管内科医师分会, 中国心血管健康联盟, 心肌梗死后心力衰竭防治专家共识工作组. 2020心肌梗死后心力衰竭防治专家共识[J]. 中国循环杂志, 2020, 35(12): 1166-1180.
|
[2]
|
李岩, 张菀桐, 翁维良. 翁维良教授治疗心肌梗死后慢性心力衰竭经验举例[J]. 天津中医药, 2021, 38(8): 976-981.
|
[3]
|
卫靖靖, 朱正望, 彭广操, 等. 基于数据挖掘探究中药治疗心肌梗死后心力衰竭的用药规律[J]. 中国中药杂志, 2022, 47(20): 5654-5661.
|
[4]
|
王玥, 欧石清, 张稳. 微小RNA调控心肌梗死后心肌肥大的研究进展[J]. 中国老年学杂志, 2022, 42(3): 756-759.
|
[5]
|
Hu, Y., Wang, X., Ding, F., et al. (2022) Periostin Renders Cardiomyocytes Vulnerable to Acute Myocardial Infarction via Pro-Apoptosis. ESC Heart Fail, 9, 977-987. https://doi.org/10.1002/ehf2.13675
|
[6]
|
Gu, H., Duan, Y., Li, S., et al. (2022) MiR-96-5p Regulates Myocardial Infarction-Induced Cardiac Fibrosis via Smad7/Smad3 Pathway. Acta Biochimica et Biophysica Sinica, 54, 1874-1888. https://doi.org/10.3724/abbs.2022175
|
[7]
|
Li, C., Fang, M., Lin, Z., et al. (2021) MicroRNA-24 Protects against Myocardial Ischemia-Reperfusion Injury via the NF-κB/TNF-α Pathway. Mental and Therapeutic Medicine, 22, Article No. 1288. https://doi.org/10.3892/etm.2021.10723
|
[8]
|
Zhang, X., Chen, Q., Zhao, J., et al. (2023) A Four-Compound Remedy AGILe Protected H9c2 Cardiomyocytes against Oxygen Glucose Deprivation via Targeting the TNF-α/NF-κB Pathway: Implications for the Therapy of Myocardial Infarction. Frontiers in Pharmacology, 14, Article 1050970. https://doi.org/10.3389/fphar.2023.1050970
|
[9]
|
Fan, F., Duan, Y., Yang, F., et al. (2020) Deletion of Heat Shock Protein 60 in Adult Mouse Cardiomyocytes Perturbs Mitochondrial Protein Homeostasis and Causes Heart Failure. Cell Death & Differentiation, 27, 587-600. https://doi.org/10.1038/s41418-019-0374-x
|
[10]
|
Al Aseri, Z.A., Habib, S.S. and Marzouk, A. (2019) Predictive Value of High Sensitivity C-Reactive Protein on Progression to Heart Failure Occurring after the First Myocardial Infarction. Vascular Health and Risk Management, 15, 221-227. https://doi.org/10.2147/VHRM.S198452
|
[11]
|
Kiuchi, M.G., Nolde, J.M., Villacorta, H., et al. (2019) New Approaches in the Management of Sudden Cardiac Death in Patients with Heart Failure-Targeting the Sympathetic Nervous System. International Journal of Molecular Sciences, 20, Article 2430. https://doi.org/10.3390/ijms20102430
|
[12]
|
Cespon-Fernandez, M., Raposeiras-Roubin, S., Abu-Assi, E., et al. (2019) Renin-Angiotensin System Blockade and Risk of Heart Failure after Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study. American Journal of Cardiovascular Drugs, 19, 487-495. https://doi.org/10.1007/s40256-019-00343-7
|
[13]
|
Lee, S.H., Rhee, T.M., Shin, D., et al. (2023) Prognosis after Discontinuing Renin Angiotensin Aldosterone System Inhibitor for Heart Failure with Restored Ejection Fraction after Acute Myocardial Infarction. Scientific Reports, 13, Article No. 3539. https://doi.org/10.1038/s41598-023-30700-1
|
[14]
|
Miyazaki, T., Otani, K., Chiba, A., et al. (2018) A New Secretory Peptide of Natriuretic Peptide Family, Osteocrin, Suppresses the Progression of Congestive Heart Failure after Myocardial Infarction. Circulation Research, 122, 742-751. https://doi.org/10.1161/CIRCRESAHA.117.312624
|
[15]
|
Niu, X., Zhang, J., Zhang, L., et al. (2019) Weighted Gene Co-Expression Network Analysis Identifies Critical Genes in the Development of Heart Failure after Acute Myocardial Infarction. Frontiers in Genetics, 10, Article 1214. https://doi.org/10.3389/fgene.2019.01214
|
[16]
|
Boye, C., Arpag, S., Burcus, N., et al. (2021) Cardioporation Enhances Myocardial Gene Expression in Rat Heart. Bioelectrochemistry, 142, Article ID: 107892. https://doi.org/10.1016/j.bioelechem.2021.107892
|
[17]
|
Swaroop, G. (2022) Post-Myocardial Infarction Heart Failure: A Review on Management of Drug Therapies. Cureus, 14, e25745. https://doi.org/10.7759/cureus.25745
|
[18]
|
Niriayo, Y.L., Asgedom, S.W., Demoz, G.T., et al. (2020) Treatment Optimization of Beta-Blockers in Chronic Heart Failure Therapy. Scientific Reports, 10, Article No. 15903. https://doi.org/10.1038/s41598-020-72836-4
|
[19]
|
Babick, A., Elimban, V., Zieroth, S., et al. (2013) Reversal of Cardiac Dysfunction and Subcellular Alterations by Metoprolol in Heart Failure Due to Myocardial Infarction. Journal of Cellular Physiology, 228, 2063-2070. https://doi.org/10.1002/jcp.24373
|
[20]
|
Wang, Y. (2022) The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency. Computational and Mathematical Methods in Medicine, 2022, Article ID: 3098726. https://doi.org/10.1155/2022/3098726
|
[21]
|
Grandinetti, V., Carlos, F.P., Antonio, E.L., et al. (2019) Photobiomodulation Therapy Combined with Carvedilol Attenuates Post-Infarction Heart Failure by Suppressing Excessive Inflammation and Oxidative Stress in Rats. Scientific Reports, 9, Article No. 9425. https://doi.org/10.1038/s41598-019-46021-1
|
[22]
|
Wu, J., Hall, A.S. and Gale, C.P. (2021) Long-Term Survival Benefit of Ramipril in Patients with Acute Myocardial Infarction Complicated by Heart Failure. Heart, 107, 389-395. https://doi.org/10.1136/heartjnl-2020-316823
|
[23]
|
Babick, A., Chapman, D., Zieroth, S., et al. (2012) Reversal of Subcellular Remodelling by Losartan in Heart Failure Due to Myocardial Infarction. Journal of Cellular and Molecular Medicine, 16, 2958-2967. https://doi.org/10.1111/j.1582-4934.2012.01623.x
|
[24]
|
Bartko, P.E., Dal-Bianco, J.P., Guerrero, J.L., et al. (2017) Effect of Losartan on Mitral Valve Changes after Myocardial Infarction. Journal of the American College of Cardiology, 70, 1232-1244. https://doi.org/10.1016/j.jacc.2017.07.734
|
[25]
|
Pradhan, A., Vohra, S. and Sethi, R. (2020) Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology. Journal of Pharmacy and Bioallied Sciences, 12, 381-390. https://doi.org/10.4103/JPBS.JPBS_338_19
|
[26]
|
Vakaliuk, I.P., Savchuk, N.V., Nesterak, R.V., et al. (2021) Influence of Complex Treatment with Magnesium and Potassium Salts of Gluconic Acid, Eplerenone and Rivaroxaban on Dynamics of Indicators of Ischemia and Myocardial Remodeling in Patients with Chronic Heart Failure after Myocardial Infarction. Wiadomości Lekarskie, 74, 2087-2093. https://doi.org/10.36740/WLek202109111
|
[27]
|
Zhou, X., Zhu, H., Zheng, Y., et al. (2022) A Systematic Review and Meta-Analysis of Sacubitril-Valsartan in the Treatment of Ventricular Remodeling in Patients with Heart Failure after Acute Myocardial Infarction. Frontiers in Cardiovascular Medicine, 9, Article 953948. https://doi.org/10.3389/fcvm.2022.953948
|
[28]
|
Xiong, B., Nie, D., Qian, J., et al. (2021) The Benefits of Sacubitril-Valsartan in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. ESC Heart Failure, 8, 4852-4862. https://doi.org/10.1002/ehf2.13677
|
[29]
|
罗桢蓝, 龚静欢, 朱凌燕. 心力衰竭患者液体管理的研究进展[J]. 中华护理杂志, 2021, 56(3): 473-477.
|
[30]
|
Tripolt, N.J., Kolesnik, E., Pferschy, P.N., et al. (2020) Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients with Acute Myocardial Infarction—The EMMY Trial. American Heart Journal, 221, 39-47. https://doi.org/10.1016/j.ahj.2019.12.004
|
[31]
|
Krasnova, M., Kulikov, A., Okovityi, S., et al. (2020) Comparative Efficacy of Empagliflozin and Drugs of Baseline Therapy in Post-Infarct Heart Failure in Normoglycemic Rats. Naunyn-Schmiedeberg’s Archives of Pharmacology, 393, 1649-1658. https://doi.org/10.1007/s00210-020-01873-7
|
[32]
|
Fraccarollo, D., Galuppo, P., Motschenbacher, S., et al. (2014) Soluble Guanylyl Cyclase Activation Improves Progressive Cardiac Remodeling and Failure after Myocardial Infarction. Cardioprotection over ACE Inhibition. Basic Research in Cardiology, 109, Article No. 421. https://doi.org/10.1007/s00395-014-0421-1
|
[33]
|
Bauersachs, J. and Nitschmann, S. (2020) Vericiguat-New Treatment Option for Patients with Heart Failure: Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA). Der Internist, 61, 989-991. https://doi.org/10.1007/s00108-020-00828-7
|
[34]
|
纪焕春, 姚福梅, 王霞, 等. 益气宁心汤联合重组人脑利钠肽治疗急性心肌梗死伴心力衰竭的临床研究[J]. 中西医结合心脑血管病杂志, 2022, 20(1): 95-99.
|
[35]
|
叶玲玲, 常青, 边佳萍, 等. 常氏二根强心汤联合还原型谷胱甘肽对心肌梗死后心力衰竭患者心功能及心肌损伤标志物的影响[J]. 中国中医药科技, 2022, 29(6): 939-942.
|
[36]
|
唐艳艳, 李飞泽, 陈琳, 等. 益气振心汤为主治疗心肌梗死后慢性心力衰竭32例[J]. 浙江中医杂志, 2019, 54(12): 889.
|
[37]
|
宋金玉, 杜鑫, 施继红, 等. 芪苈强心胶囊联合米力农对心肌梗死合并心力衰竭患者动脉血流和心功能的影响[J]. 陕西中医, 2020, 41(4): 493-495.
|
[38]
|
张志亮, 吕风华. 复方丹参滴丸联合托伐普坦治疗急性心肌梗死并发心力衰竭的临床研究[J]. 现代药物与临床, 2020, 35(2): 234-238.
|
[39]
|
史航. 冠心舒通胶囊联合氯吡格雷对急性心肌梗死并心力衰竭患者NT-ProBNP及心功能的影响[J]. 辽宁中医杂志, 2022, 49(7): 124-128.
|
[40]
|
常鑫迪, 卫靖靖, 郝轩轩, 等. 心脉隆注射液治疗急性心肌梗死后心力衰竭疗效与安全性的Meta分析[J]. 中国中药杂志, 2021, 46(5): 1250-1259.
|
[41]
|
李艳琴, 王桂芳. 血必净注射液辅助治疗急性心肌梗死伴心力衰竭的临床研究[J]. 辽宁中医杂志, 2023, 50(2): 133-136.
|
[42]
|
吕岩丽. 渐进式康复运动训练应用于急性心肌梗死后心力衰竭患者的效果分析[J]. 大医生, 2022, 7(18): 142-144.
|
[43]
|
于曼丽, 姜衡, 李彬, 等. 太极拳对老年心肌梗死后心力衰竭患者心脏功能的效果[J]. 中国康复理论与实践, 2020, 26(8): 969-974.
|
[44]
|
党晓晶, 徐丹苹, 唐芳, 等. 中西医结合II期心脏康复治疗心肌梗死后心力衰竭病人验案[J]. 中西医结合心脑血管病杂志, 2022, 20(16): 3061-3063.
|
[45]
|
朱瑞珍. 无创呼吸机辅助通气联合吗啡治疗急性心肌梗死后心力衰竭的疗效分析[J]. 中国实用医药, 2022, 17(25): 128-130.
|
[46]
|
杜耀, 朱彬彬, 刘亚慧, 等. 主动脉内球囊反搏治疗急性心肌梗死合并心原性休克的研究进展[J]. 中国心血管杂志, 2022, 27(6): 602-605.
|
[47]
|
王春丹. 连续性血液净化治疗重症心力衰竭合并肾衰竭的效果探究[J]. 中国实用医药, 2022, 17(21): 42-44.
|
[48]
|
袁莉, 孙晓宁, 王春生. 左心室辅助装置治疗心力衰竭的现状及进展[J]. 中国胸心血管外科临床杂志, 2022, 29(4): 508-513.
|
[49]
|
郑子赫, 许政, 林炘凡, 等. 心脏移植的过去、现在和未来[J]. 器官移植, 2023, 14(2): 227-234.
|
[50]
|
陈昕昀, 袁见, 郎韫哲, 等. 针灸保护心肌损伤的作用及机制研究进展[J]. 中西医结合心脑血管病杂志, 2021, 19(1): 61-64.
|
[51]
|
杨璐, 衣欣, 王晓宁, 等. 便秘推拿联合穴位按摩治疗老年气虚血瘀证心力衰竭患者便秘效果[J]. 中国老年学杂志, 2020, 40(7): 1359-1362.
|
[52]
|
李凤, 程晓昱, 蒋文君, 等. 复方真武冲剂内服配合穴位贴敷治疗慢性心衰50例临床观察[C]//中国中西医结合学会第八届虚证与老年医学专业委员会. 中国中西医结合学会第八届虚证与老年医学专业委员会、中国老年学和老年医学学会中西医结合分会、江苏省中医药学会老年医学专业委员会2019年学术年会论文集. 2019: 107-111.
|